InnoSer
InnoSer is a European preclinical CRO operating AAALAC-accredited facilities in the Netherlands and Belgium, providing fee-for-service translational research — including proprietary genetically modified mouse models, behavioral testing, biomarker bioanalysis, and histopathology — to 200+ pharmaceutical and biotechnology clients across neurology, oncology, nephrology, immunology, cardiovascular, and metabolic disease.
- Company typePrivate
- Founded2016
- HeadquartersDiepenbeek, Belgium
- Headcount11–50
- GTM typeB2B
- OfferingServices
What InnoSer does
InnoSer is a privately held European preclinical Contract Research Organization (CRO) operating from AAALAC-accredited facilities in Leiden, Netherlands (since 2016) and Diepenbeek, Belgium (since 2020). Founded in 2011 as InnoSer Laboratories BV, the company provides fee-for-service translational preclinical research for pharmaceutical and biotechnology clients, with a customer base of 200+ that includes large pharma (Roche, AstraZeneca, Daiichi-Sankyo, Bayer, Novo Nordisk) and biotech firms ranging from mid-market (Bial, Carthera, Agomab) to early-stage startups (Montis, Upyther, Illimis, Regel, NTrans).
The core platform combines proprietary genetically modified mouse models, an integrated behavioral testing battery (PhenoTyper home-cages with AHCODA analytics, CatWalk XT gait analysis, Morris Water Maze, rotarod, grip strength), histopathology/IHC, MSD-based biomarker bioanalysis (Aβ42/40, pTau181, total Tau, NfL in plasma/CSF), longitudinal ultrasound imaging, and 3R-compliant vivarium management. Notable proprietary assets include the Tau[P301S] and APP[V717I]xTau[P301S] transgenic Alzheimer's models, an ADPKD P10/P18/P40 tamoxifen-inducible platform with FDA/EMA-aligned total kidney volume biomarker readouts, and the SonoCloud ultrasound-mediated BBB drug-delivery service. The InnoSer Acceleration Program (ISAP) extends the offering to startups and academic spinoffs with tiered milestone-based support and vivarium rental.
InnoSer's go-to-market combines direct enterprise sales (Business Development Managers and Product Managers), conference-led demand generation across therapeutic venues (AD/PD, CKD Drug Development Summit, Global NASH Congress), and content marketing via scientific newsletters and downloadable technical leaflets. Pricing is quote-based with an explicit 'transparent upfront costs, no hidden fees' value proposition. Revenue model is professional services (project-based CRO contracts), with no public revenue disclosure and only one disclosed funding round (~€1M from Limburgse Reconversie Maatschappij in September 2016). Core scientific alliances include Sylics (Synaptologics BV), VU University Amsterdam's CNCR, Novo Nordisk, MAT BioTech, and TU Eindhoven.
InnoSer firmographics
Firmographics- Name
- InnoSer
- Legal name
- InnoSer Laboratories BV
- Website
- https://innoserlaboratories.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- InnoSer is a European preclinical CRO operating AAALAC-accredited facilities in the Netherlands and Belgium, providing fee-for-service translational research — including proprietary genetically modified mouse models, behavioral testing, biomarker bioanalysis, and histopathology — to 200+ pharmaceutical and biotechnology clients across neurology, oncology, nephrology, immunology, cardiovascular, and metabolic disease.
- Ownership category
- akta.pro rank
InnoSer industry classification
Industry- Product category
- Preclinical Contract Research
- NAICS
- Other Scientific and Technical Consulting Services (54169)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)
- akta.pro secondary industries
- Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC), Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)
Keywords
Where InnoSer is headquartered
LocationHeadquarters
- HQ city
- Diepenbeek
- HQ country
- Belgium
- HQ region
- Europe
Offices2 records
Markets served
InnoSer business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Preclinical CRO Contract Research Services: Fee-for-service preclinical contract research spanning in vivo pharmacology, in vitro assays, behavioral testing, histopathology, biomarker bioanalysis, and colony management; project-based engagement with dedicated study directors and customized study design per client program.
- InnoSer Acceleration Program (ISAP) and Vivarium Rental: Customized compound development program for startups and academic spinoffs offering flexible support tiers, access to fully equipped in vitro/in vivo rental spaces, and tailored milestone-based research support.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | — | Quote-based, project-tier CRO service pricing |
Go-to-market motion4 records
Distribution channels3 records
Marketing channels7 records
InnoSer product offering
Product offeringCore offering
InnoSer is a European preclinical Contract Research Organization (CRO) providing fee-for-service drug discovery and preclinical development offerings to biotech and pharmaceutical companies. Its core services span in vivo pharmacology using proprietary and validated genetically modified mouse models, rodent behavioral testing, histopathology and biomarker bioanalysis, colony management, and vivarium/facility rental, organized across therapeutic areas including neurology, oncology, immunology, nephrology, metabolic, and cardiovascular disease.
Product overview
InnoSer is a European preclinical contract research organization (CRO) offering a unified services platform for drug discovery and translational research, structured around core service modules (In Vivo Models, Rodent Behavioral Testing, Pathology, Colony Management, and Facility Management) and the InnoSer Acceleration Program (ISAP) compound development program. The platform is organized by research area expertise — including Neurology, Oncology, Immunology, Nephrology, Metabolic, and Cardiovascular services — and delivered through an extensive portfolio of disease-specific mouse models such as the Tau[P301S], APP[V717I] x Tau[P301S], Tau Seeding Mouse Models, P40 ADPKD Mouse Model, and broader Alzheimer's Disease and Rare Disease Mouse Model collections. Together, these products and modules support clients from target validation through IND-enabling preclinical development.
Differentiator
Problem solved
Functional benefit
Companies that use InnoSer
Customer profileNamed customers14 records
Segments7 records
Ideal customer profiles4 records
InnoSer technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature10 records
InnoSer partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered minor and core.
- TU EindhovenminorInnoSer maintains close collaboration with TU Eindhoven as a consortium partner; product manager Tim Rodenburg regularly visits TU Eindhoven's research groups (e.g., the Luttge group) for collaborative work.
- Sylics (Synaptologics BV)coreSylics is a key scientific collaboration partner on neurodegenerative disease behavioral phenotyping. Together they developed PhenoTyper home-cage AHCODA analytical methods for discriminating neurodegeneration from healthy aging (presented at AD/PD 2023). Sylics is also a collaboration partner on NAFLD/cognitive deficit research presented at the 6th Global NASH Congress 2023 with Novo Nordisk. Several shared scientific staff (Bastijn Koopmans, Maarten Loos, Joshua Obermayer) contribute to both organizations.
- VU University Amsterdam - Center for Neurogenomics and Cognitive Research (CNCR)coreAcademic research collaboration on neurodegenerative disease behavioral phenotyping, co-developing home-cage behavior analysis methods with Sylics. Multiple CNCR faculty (Sabine Spijker, Ronald E. van Kesteren, Matthijs Verhage, August B. Smit) co-authored the AD/PD 2023 poster on discriminating neurodegeneration from healthy aging.
- Novo Nordisk A/ScoreCo-development partner on a pilot study investigating western-style diet-induced cognitive deficits in C57BL/6J mice (presented at 6th Global NASH Congress 2023, London). The collaboration established a translatable mouse model platform for testing therapeutics targeting diet-induced cognitive impairment in metabolic disorders.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
InnoSer competitors and assessment
Company assessmentBroad incumbents
- Labcorp (Covance): Global CRO with extensive preclinical research services including in vivo pharmacology, safety assessment, and biomarker capabilities. Competes with InnoSer for pharma preclinical outsourcing budgets via its larger scale and integrated early-to-clinical development offerings.
- Pharmaron: China/UK/US-headquartered CRO with preclinical in vivo, DMPK, safety, and integrated discovery services. Overlaps with InnoSer in preclinical CRO services but offers much broader, integrated drug discovery-to-development scope.
- Wuxi AppTec: Global preclinical and clinical CRO with extensive rodent model, in vivo pharmacology, and bioanalytical capabilities serving pharma and biotech. Comparable in service scope but competes from a much larger, Asia-rooted platform.
- Charles River Laboratories: Global preclinical CRO with extensive rodent model, in vivo pharmacology, and safety assessment capabilities across oncology, neurology, and metabolic disease. Overlaps with InnoSer's full preclinical CRO platform but at vastly larger scale and broader geographic footprint.
- Eurofins Scientific: European life sciences testing and CRO conglomerate offering preclinical, bioanalytical, and biomarker services. Adjacent competitor in bioanalytical/biomarker work and broader preclinical testing, with substantially greater scale and global footprint than InnoSer.
- Evotec: European drug discovery and preclinical CRO with multi-therapeutic area coverage, proprietary platforms, and partnerships with major pharma. Comparable in therapeutic breadth and European positioning to InnoSer, though operating at much larger scale and integrated discovery-to-clinical scope.
Emerging players
- Sylics (Synaptologics BV): Dutch behavioral phenotyping specialist that co-developed PhenoTyper/AHCODA with InnoSer; provides automated home-cage behavior analytics. Adjacent rather than directly competing, but operates in overlapping neurodegenerative disease phenotyping workflows with shared scientific staff.
Direct peers
- QPS Holdings: Mid-sized CRO specializing in preclinical and clinical research across neuroscience, metabolic disease, and other therapeutic areas. Comparable in therapeutic focus (notably neurology and metabolic) and ability to serve mid-market biotech and large pharma preclinical needs.
- Crown Bioscience (JSR Life Sciences): Preclinical CRO with deep oncology and immuno-oncology model portfolios (syngeneic, CDX, PDX, humanized models) plus translational biomarker capabilities. Directly comparable to InnoSer's oncology CRO services and biomarker offerings.
- PsychoGenics: US-based preclinical CRO specializing in behavioral phenotyping and neurodegenerative disease models using transgenic mice and AI-driven analytics (e.g., NeuroCube). Closely comparable to InnoSer's neurology/CNS preclinical services and automated behavior platforms like PhenoTyper/AHCODA.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
InnoSer social profiles
Digital presenceInnoSer compliance and trust
Trust signalCompliance2 records
InnoSer financial estimates
Financial estimateRevenue estimate
Valuation estimate
InnoSer leadership team
Management profileNumber of profiles
Profiles11 records
InnoSer funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
InnoSer M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about InnoSer
What does InnoSer do?
InnoSer is a European preclinical Contract Research Organization (CRO) providing fee-for-service drug discovery and preclinical development offerings to biotech and pharmaceutical companies. Its core services span in vivo pharmacology using proprietary and validated genetically modified mouse models, rodent behavioral testing, histopathology and biomarker bioanalysis, colony management, and vivarium/facility rental, organized across therapeutic areas including neurology, oncology, immunology, nephrology, metabolic, and cardiovascular disease.
Is InnoSer a public or private company?
InnoSer is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was InnoSer founded?
InnoSer was founded in 2016. It employs 11 to 50 people.
Where is InnoSer based?
InnoSer is headquartered in Diepenbeek, Belgium, in the Europe region.
How does InnoSer make money?
Two revenue lines are on record. Preclinical CRO Contract Research Services are the primary driver. The others are innoSer Acceleration Program (ISAP) and Vivarium Rental.
Who are InnoSer's main competitors?
Broad incumbents on record are Labcorp (Covance), Pharmaron, Wuxi AppTec, Charles River Laboratories, Eurofins Scientific and Evotec. Sylics (Synaptologics BV) is listed as an emerging player. Direct peers are QPS Holdings, Crown Bioscience (JSR Life Sciences) and PsychoGenics.
Does InnoSer have an API?
No public API is recorded for InnoSer.
What industry is InnoSer in?
InnoSer's product category is Preclinical Contract Research. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAC, Toxicology & Safety Assessment CROs (GLP). Its NAICS code is 54169 and its SIC code is 8731.